Online citations, reference lists, and bibliographies.
← Back to Search

Encapsulation Of The Immune Potentiators MPL And RC529 In PLG Microparticles Enhances Their Potency.

J. Kazzaz, M. Singh, M. Ugozzoli, James Chesko, Elawati Soenawan, D. O'hagan
Published 2006 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE Monophosphoryl lipid A (MPL) and the synthetic LPS mimetic RC529, encapsulated in poly(lactide-co-glycolide) (PLG) microparticles, were evaluated as immune potentiators in the presence of either HIV-1 gp120 protein or antigen from Neisseria meningitidis serotype B (Men B). The immunogenicity of these formulations was evaluated in mice and compared to CpG containing oligonucleotide. This work was done as part of an ongoing effort to enhance the potency of vaccine candidates against HIV and Men B. METHODS Microparticles were made by a solvent evaporation method. Blank microparticles as well as microparticles with encapsulated MPL or RC529 were made using the PLG polymer RG503 and the ionic surfactant Dioctylsulfosuccinate by the water-in-oil-in-water emulsion technique. Antigens from HIV-1 and Men B were adsorbed on the surface of these anionic microparticles and the final formulations characterized for protein loading, release, and integrity. The formulations were then tested in mice for their ability to elicit antibodies and bactericidal activity in comparison with CpG containing oligonucleotide. RESULTS We have found that adding soluble immune potentiators to Men B antigen formulated on PLG microparticles significantly enhanced the immune response to a level comparable to that obtained using CpG. In a separate study, we found that encapsulating MPL or RC529 in PLG microparticles further enhanced the response in comparison to soluble CpG, which is our control group. Similarly, adding soluble immune potentiators to gp120 antigen formulated on PLG microparticles resulted in a significant enhancement of the immune response. Moreover, delivering MPL or RC529 encapsulated in PLG microparticles with gp120 adsorbed on PLG microparticles, resulted in even further enhancement of serum titers over those obtained with soluble immune potentiators. These titers were comparable to or greater than those obtained with soluble CpG, the control group. This effect was observed for both antigens regardless of whether or not the immune potentiator and the antigen were used with the same or with separate particles. In conclusion, the advantages of encapsulating MPL and RC529 lie not only in the enhanced immune response they elicit, but also in the convenience of handling these relatively insoluble compounds, and flexibility in vaccine design. The fact that MPL and RC529 are readily soluble in methylene chloride used for the manufacturing of PLG microparticles makes it easy to avoid solubility issues. Moreover, formulating antigen and immune potentiator with the same particle offers an attractive approach to vaccine delivery.
This paper references
10.1084/JEM.188.11.2091
Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide
C. Kirschning (1998)
10.1002/JPS.10538
Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.
M. Singh (2004)
10.1586/14760584.2.2.269
Microparticles as vaccine adjuvants and delivery systems
D. O'hagan (2003)
10.1002/JBM.10019
Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo.
K. D. Newman (2002)
10.1016/S0264-410X(99)00572-1
Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.
J. Baldridge (2000)
10.1084/jem.20020073
Adjuvants of Immunity
A. Bendelac (2002)
10.1002/JBM.820221002
Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers.
Y. Tabata (1988)
10.1023/A:1012269226066
Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA
M. Singh (2004)
10.1172/JCI8541
Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide.
E. Lien (2000)
10.1128/CMR.7.3.277
Molecular adjuvants and immunomodulators: new approaches to immunization.
A. Johnson (1994)
10.1128/IAI.65.8.3239-3247.1997
Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages.
C. Salkowski (1997)
10.1126/SCIENCE.287.5459.1816
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.
M. Pizza (2000)
10.1007/978-1-4615-1823-5_8
Adjuvant properties of aluminum and calcium compounds.
R. Gupta (1995)
10.1038/NBT0298-153
Improving protein therapeutics with sustained-release formulations
S. D. Putney (1998)
Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
K. Maloy (1994)
10.1016/S0168-3659(00)00226-1
Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.
J. Kazzaz (2000)
10.1016/0264-410X(95)00184-3
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
A. Moore (1995)
10.4049/jimmunol.164.11.5998
Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1
M. Muzio (2000)
Signaling events induced by lipopolysaccharide-activated toll-like receptor 2.
R. B. Yang (1999)
10.1128/JVI.77.20.11244-11259.2003
Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate
I. Srivastava (2003)
10.1006/METH.1999.0834
Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
J. Baldridge (1999)
10.1038/35100529
Toll-like receptors and innate immunity
R. Medzhitov (2001)
Vaccine design : the subunit and adjuvant approach
M. F. Powell (1995)
10.1016/S0140-6736(04)17398-4
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
D. Harper (2004)
10.1016/0264-410X(95)00011-O
Adjuvants for human vaccines--current status, problems and future prospects.
R. Gupta (1995)
10.1016/S0264-410X(99)00062-6
The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
A. Moore (1999)
10.1080/078538902321117850
Meningococcal disease: treatment and prevention
R. Wall (2002)
10.1007/s11095-004-7666-6
Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not
M. Singh (2004)
10.1126/SCIENCE.3107127
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.
C. Snapper (1987)
10.1016/S0952-7915(98)80024-1
An ancient system of host defense.
R. Medzhitov (1998)
10.2165/00063030-200216050-00001
Meningococcal Vaccines
Simone S. Wildes (2012)
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
H. Davis (1998)
10.1128/JVI.77.10.6087-6092.2003
Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles
G. Otten (2003)
10.4049/jimmunol.164.6.3255
CD14 Employs Hydrophilic Regions to “Capture” Lipopolysaccharides
M. Cunningham (2000)
10.1007/978-1-4615-1823-5_21
Monophosphoryl Lipid A as an Adjuvant
J. T. Ulrich (1995)
10.1016/S0140-6736(04)17223-1
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
P. Alonso (2004)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I1.10
Biodegradable microspheres in drug delivery.
H. Okada (1995)



This paper is referenced by
10.1016/J.JCONREL.2006.04.006
Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Sudhir Pai Kasturi (2006)
10.1007/978-1-4939-6445-1_1
Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
Ruchi R Shah (2017)
10.1039/b914943k
Designing polymeric particles for antigen delivery.
S. de koker (2011)
10.1016/j.ijpharm.2012.04.047
Vaccine delivery carriers: insights and future perspectives.
J. Correia-Pinto (2013)
Novel particulate BCG-loaded delivery system for mucosal immunization against tuberculosis
L. A. Caetano (2016)
10.1016/S1773-2247(08)50004-9
Micro-organism-like nanoparticles for oral antigen delivery
Hesham H. Salman (2008)
10.1016/B978-0-12-394296-8.00021-X
Adjuvant Strategies for Vaccines: The Use of Adjuvants within the Cancer Vaccine Setting
Claire H. A. Hearnden (2013)
10.2174/1568026615666150701115508
Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines.
Eva Zupančič (2016)
10.1038/nbt1261
Vaccine manufacturing: challenges and solutions
J. Ulmer (2006)
10.1586/erv.09.160
Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists
M. Black (2010)
10.1016/j.xphs.2018.02.007
Development of Adjuvanted Solid Fat Nanoemulsions for Pulmonary Hepatitis B Vaccination.
Sunita Minz (2018)
10.1016/j.ijbiomac.2020.04.048
Bicistronic DNA vaccine macromolecule complexed with poly lactic-co-glycolic acid-chitosan nanoparticles enhanced the mucosal immunity of Labeo rohita against Edwardsiella tarda infection.
Tasok Leya (2020)
10.1126/sciimmunol.abb1025
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates
S. Kasturi (2020)
10.2147/VMRR.S68905
Infectious bursal disease virus in poultry: current status and future prospects
T. Alkie (2016)
10.1016/j.jddst.2019.101327
In-vitro and in-vivo comparison of rSAG1-loaded PLGA prepared by encapsulation and adsorption methods as an efficient vaccine against Toxoplasma gondii”
Mojgan Allahyari (2020)
Transcutaneous immunization using lipid colloidal systems and microneedles
Teerawan Rattanapak (2013)
10.1002/jps.21523
Vaccine adjuvants: current challenges and future approaches.
Jennifer H. Wilson-Welder (2009)
10.1007/978-1-4614-0554-2_21
Injectable PLGA Systems for Delivery of Vaccine Antigens
Vesna Milacic (2012)
10.2217/nnm.11.171
Nanoimmunotherapy: application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells.
Z. Zhang (2012)
10.1016/j.jconrel.2018.09.020
Investigation of tunable acetalated dextran microparticle platform to optimize M2e‐based influenza vaccine efficacy
Naihan Chen (2018)
10.1016/j.ejpb.2015.01.021
On the synthesis of mucus permeating nanocarriers.
V. Bourganis (2015)
10.31274/ETD-180810-561
In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery
Wilson Welder (2009)
10.1002/ADFM.201103151
Modulation of Dendritic Cells by Lipid Grafted Polyelectrolyte Microcapsules
Marie-Luce De Temmerman (2012)
10.1016/j.nano.2013.01.002
Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells.
T. Démoulins (2013)
10.1016/j.smim.2013.05.007
Vaccine adjuvant formulations: a pharmaceutical perspective.
Luis M Brito (2013)
10.1038/nrmicro1681
The perfect mix: recent progress in adjuvant research
B. Guy (2007)
10.1016/j.ejpb.2019.06.022
Self-assembled amphiphilic copolymers as dual delivery system for immunotherapy.
Thomas Trimaille (2019)
10.1586/14787210.2013.845524
Delivery of host cell-directed therapeutics for intracellular pathogen clearance
Michael A. Collier (2013)
10.2217/nnm.14.156
Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
Vincent Pavot (2014)
Adjuvants: an essential component of neisseria vaccines
Reinaldo Acevedo (2009)
10.1007/s40005-019-00439-x
Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles
Enas M. Elmowafy (2019)
10.3390/md14050090
Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation
Liliana Aranha Caetano (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar